Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (101-110 of 158) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndromeAzim M Mohamedali, Alexander E Smith, Joop Gaken, et al.
Annals of Hematology|August 6, 2018
Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapyEsther Schuler, Natalie Zadrozny, Sabine Blum, et al.
Blood|March 6, 2002
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cellsUlrich Steidl, Ralf Kronenwett, Ulrich-Peter Rohr, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Oncology Research and Treatment|August 21, 2024
Introduction of a New Satellite Model for Participation in Clinical Trials in a Consortial Comprehensive Cancer Center with Four University Hospitals in GermanyJohanna Teloh-Benger, Susanne Isfort, Norbert Gattermann, et al.
Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Annals of Hematology|June 27, 2025
Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysisKatharina Anna Rauhe, Annika Kasprzak, Felicitas Schulz, et al.
Leukemia & Lymphoma|September 16, 2017
Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the foreHans Tilman Steinmetz, Ulrich Germing, Annette Sauer, et al.
Annals of Hematology|April 12, 2026
Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registryJonas Welsch, Felicitas Schulz, Annika Kasprzak, et al.
European Journal of Haematology|March 13, 2003
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantationFrank Neumann, Caroline Herold, Barbara Hildebrandt, et al.
Pageof 16

Showing results (101-110 of 158) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndromeAzim M Mohamedali, Alexander E Smith, Joop Gaken, et al.
Annals of Hematology|August 6, 2018
Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapyEsther Schuler, Natalie Zadrozny, Sabine Blum, et al.
Blood|March 6, 2002
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cellsUlrich Steidl, Ralf Kronenwett, Ulrich-Peter Rohr, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Oncology Research and Treatment|August 21, 2024
Introduction of a New Satellite Model for Participation in Clinical Trials in a Consortial Comprehensive Cancer Center with Four University Hospitals in GermanyJohanna Teloh-Benger, Susanne Isfort, Norbert Gattermann, et al.
Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Annals of Hematology|June 27, 2025
Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysisKatharina Anna Rauhe, Annika Kasprzak, Felicitas Schulz, et al.
Leukemia & Lymphoma|September 16, 2017
Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the foreHans Tilman Steinmetz, Ulrich Germing, Annette Sauer, et al.
Annals of Hematology|April 12, 2026
Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registryJonas Welsch, Felicitas Schulz, Annika Kasprzak, et al.
European Journal of Haematology|March 13, 2003
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantationFrank Neumann, Caroline Herold, Barbara Hildebrandt, et al.
Pageof 16